182 related articles for article (PubMed ID: 37407886)
21. Pathology, therapy and prognosis of papillary renal carcinoma.
Fernandes DS; Lopes JM
Future Oncol; 2015; 11(1):121-32. PubMed ID: 25572787
[TBL] [Abstract][Full Text] [Related]
22. Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma.
Christensen BR; Hajja YM; Koshkin V; Barata PC
Curr Treat Options Oncol; 2021 Jan; 22(2):15. PubMed ID: 33438115
[TBL] [Abstract][Full Text] [Related]
23. Cytomorphologic comparison of type 1 and type 2 papillary renal cell carcinoma: A retrospective analysis of 28 cases.
Magers MJ; Perrino CM; Cramer HM; Wu HH
Cancer Cytopathol; 2019 Jun; 127(6):370-376. PubMed ID: 31091016
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
25. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
27. Renal cell carcinoma: progress against an elusive tumor.
Motzer RJ
Semin Oncol; 2000 Apr; 27(2):113-4. PubMed ID: 10768590
[No Abstract] [Full Text] [Related]
28. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
29. Papillary renal cell carcinoma: Review.
Mendhiratta N; Muraki P; Sisk AE; Shuch B
Urol Oncol; 2021 Jun; 39(6):327-337. PubMed ID: 34034966
[TBL] [Abstract][Full Text] [Related]
30. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
31. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous response to target therapy in metastatic papillary renal cell carcinoma evaluated by morphologic and metabolic multimodality imaging: A case report.
Naglieri E; Niccoli Asabella A; Nappi AG; Carella C; Ferrari C; Rubini G
Medicine (Baltimore); 2019 Dec; 98(50):e18093. PubMed ID: 31852068
[TBL] [Abstract][Full Text] [Related]
33. Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Goebell PJ; Ivanyi P; Bedke J; Bergmann L; Berthold D; Boegemann M; Busch J; Doehn C; Krege S; Retz M; Amsberg GV; Grimm MO; Gruenwald V
Future Oncol; 2020 Oct; 16(29):2307-2328. PubMed ID: 32964728
[TBL] [Abstract][Full Text] [Related]
34. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases.
Skenderi F; Ulamec M; Vanecek T; Martinek P; Alaghehbandan R; Foix MP; Babankova I; Montiel DP; Alvarado-Cabrero I; Svajdler M; Dubinský P; Cempirkova D; Pavlovsky M; Vranic S; Daum O; Ondic O; Pivovarcikova K; Michalova K; Hora M; Rotterova P; Stehlikova A; Dusek M; Michal M; Hes O
Ann Diagn Pathol; 2017 Apr; 27():48-56. PubMed ID: 28325361
[TBL] [Abstract][Full Text] [Related]
35. Oncocytic papillary renal cell carcinoma: A clinicopathological and genetic analysis and indolent clinical course in 14 cases.
Han G; Yu W; Chu J; Liu Y; Jiang Y; Li Y; Zhang W
Pathol Res Pract; 2017 Jan; 213(1):1-6. PubMed ID: 27931799
[TBL] [Abstract][Full Text] [Related]
36. Papillary Renal Cell Carcinoma (PRCC): An Update.
Akhtar M; Al-Bozom IA; Al Hussain T
Adv Anat Pathol; 2019 Mar; 26(2):124-132. PubMed ID: 30507616
[TBL] [Abstract][Full Text] [Related]
37. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
38. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives.
Pagani F; Colecchia M; Sepe P; Apollonio G; Claps M; Verzoni E; de Braud F; Procopio G
Cancer Treat Rev; 2019 Sep; 79():101891. PubMed ID: 31491662
[TBL] [Abstract][Full Text] [Related]
39. Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma: A STROBE-Compliant Observational Study.
Ge YZ; Xu LW; Xu Z; Wu R; Xin H; Zhu M; Lu TZ; Geng LG; Liu H; Zhou CC; Yu P; Zhao YC; Hu ZK; Zhao Y; Zhou LH; Wu JP; Li WC; Zhu JG; Jia RP
Medicine (Baltimore); 2015 Apr; 94(16):e767. PubMed ID: 25906110
[TBL] [Abstract][Full Text] [Related]
40. A molecular classification of papillary renal cell carcinoma.
Yang XJ; Tan MH; Kim HL; Ditlev JA; Betten MW; Png CE; Kort EJ; Futami K; Furge KA; Takahashi M; Kanayama HO; Tan PH; Teh BS; Luan C; Wang K; Pins M; Tretiakova M; Anema J; Kahnoski R; Nicol T; Stadler W; Vogelzang NG; Amato R; Seligson D; Figlin R; Belldegrun A; Rogers CG; Teh BT
Cancer Res; 2005 Jul; 65(13):5628-37. PubMed ID: 15994935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
